Breakthrough candidemia in patients with cancer differs from de novo candidemia in host factors and Candida species but not intensity

Infection Control and Hospital Epidemiology

Volumn 23, Issue 9, 2002, Pages 542-545

  Kontoyiannis, Dimitrios P ^a   Reddy, Bhavanandra T ^a   Hanna, Hend ^a   Bodey, Gerald P ^a   Tarrand, Jeffrey ^a   Raad, Issam I ^a  

^a UNIVERSITY OF TEXAS MD ANDERSON CANCER CENTER   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

ADOLESCENT; ADULT; AGED; ARTICLE; BLOOD CULTURE; CANCER CENTER; CANCER PATIENT; CANDIDA; CANDIDA GLABRATA; CANDIDA KRUSEI; CANDIDIASIS; CATHETER; CHILD; CONTROLLED STUDY; FEMALE; HOSPITAL INFECTION; HUMAN; INFECTION RISK; LEUKEMIA; MAJOR CLINICAL STUDY; MALE; NEUTROPENIA; QUANTITATIVE ANALYSIS; RETROSPECTIVE STUDY;

EID: 0036734195     PISSN: 0899823X     EISSN: None     Source Type: Journal    
DOI: 10.1086/502104     Document Type: Article

References (10)

1. The epidemiology of hematogenous candidiasis caused by different Candida species
2. Candidemia in cancer patients: A prospective, multi-center surveillance study by the Invasive Fungal Infection Group (IFIG) of the European Organization for Research and Treatment of Cancer (EORTC)
3. The changing face of candidemia: Emergence of non-Candida albicans species and antifungal resistance
4. Breakthrough fungemia in neutropenic patients
5. Breakthrough candidemia during antifungal treatment with fluconazole in patients with hematologic malignancies
6. Editorial response: Catheters and candidemia
7. Clinical comparison of the resin-containing BACTEC26 Plus and the isolator 10 blood culturing systems
8. Failure of empirical therapy with amphotericin B to prevent candidemia in neutropenic patients with cancer
9. Risk factors and predictors of outcome in cancer patients with breakthrough candidemia
10. Comparison of in vivo activity of fluconazole with that of amphotericin B against Candida tropicalis, Candida glabrata, and Candida krusei